The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and β-Pancreatic Cells and in Obesity and Hyperglycemia
Abstract
Context: Cannabinoid CB1 receptor blockade decreases weight and hyperinsulinemia in obese animals and humans in a way greatly independent from food intake. Objective: The objective of this study was to investigate the regulation and function of the endocannabinoid system in adipocytes and pancreatic β-cells. Design, Setting, and Patients: Mouse 3T3-F442A adipocytes and rat insulinoma RIN-m5F β-cells, pancreas and fat from mice with diet-induced obesity, visceral and sc fat from patients with body mass index equal to or greater than 30 kg/m2, and serum from normoglycemic and type 2 diabetes patients were studied. Main Outcome Measure: Endocannabinoid enzyme and adipocyte protein expression, and endocannabinoid and insulin levels were measured. Results: Endocannabinoids are present in adipocytes with levels peaking before differentiation, and in RIN-m5F β-cells, where they are under the negative control of insulin. Chronic treatment of adipocytes with insulin is accompanied by permanently elevated endocannabinoid signaling, whereas culturing of RIN-m5F β-cells in high glucose transforms insulin down-regulation of endocannabinoid levels into up-regulation. Epididymal fat and pancreas from mice with diet-induced obesity contain higher endocannabinoid levels than lean mice. Patients with obesity or hyperglycemia caused by type 2 diabetes exhibit higher concentrations of endocannabinoids in visceral fat or serum, respectively, than the corresponding controls. CB1 receptor stimulation increases lipid droplets and decreases adiponectin expression in adipocytes, and it increases intracellular calcium and insulin release in RIN-m5F β-cells kept in high glucose. Conclusions: Peripheral endocannabinoid overactivity might explain why CB1 blockers cause weight-loss independent reduction of lipogenesis, of hypoadiponectinemia, and of hyperinsulinemia in obese animals and humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559 · cited 2×
“For example, leptin controls the levels of anandamide through regulation of FAAH, and of 2-AG through regulation of the levels of its biosynthetic precursor (7, 23, 24).”
BackgroundVan Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Cota, D., Marsicano, G., Tschöp, M., Grübler, Y., Flachskamm, C., Schubert, M., Auer, D., Yassouridis, A., Thöne-Reineke, C., Ortmann, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17725 · Cited by 1,168
Self-citationOsei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-White, J., Mackie, K., Offertáler, L., Wang, L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523057 · Cited by 1,101
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Ram�rez-Zacar�as, J. L., Castro-Mu�ozledo, F., & Kuri-Harcuch, W. (1992) · Histochemistry · doi:10.1007/bf00316069 · Cited by 1,008
Kirkham, T. C., Williams, C. M., Fezza, F., & Marzo, V. D. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704767 · Cited by 788
Endocannabinoid control of food intake and energy balance
Di Marzo, V., & Matias, I. (2005) · Nature Neuroscience · doi:10.1038/nn1457 · Cited by 743
Self-citationActivation of the peripheral endocannabinoid system in human obesity
Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2838 · Cited by 686
Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J. P., Le Fur, G., Oury-Donat, F., & Soubrié, P. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.908 · Cited by 593
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M., & Soubrié, P. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802583 · Cited by 583
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice
Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J.-P., & Soubrié, P. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00545.2002 · Cited by 566
Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors
Williams, C. M., & Kirkham, T. C. (1999) · Psychopharmacology · doi:10.1007/s002130050953 · Cited by 505
Appetite suppression and weight loss after the cannabinoid antagonist SR 141716
Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R., & Gessa, G. L. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00322-1 · Cited by 487
Jbilo, O., Ravinet‐Trillou, C., Arnone, M., Buisson, I., Bribes, E., Péleraux, A., Pénarier, G., Soubrié, P., Le Fur, G., Galiègue, S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3177fje · Cited by 346
Berrendero, F., Sepe, N., Ramos, J. A., Di Marzo, V., & Fern�ndez-Ruiz, J. J. (1999) · Synapse · doi:10.1002/(sici)1098-2396(19990901)33:3<181::aid-syn3>3.0.co;2-r · Cited by 289
Self-citationEndocannabinoid signalling in the blood of patients with schizophrenia.
Marchi, N. D., PETROCELLIS, L. D., Orlando, P., Daniele, F., Fezza, F., & Marzo, V. D. (2003) · Lipids in Health and Disease · doi:10.1186/1476-511x-2-5 · Cited by 275
Self-citationMonteleone, P., Matias, I., Martiadis, V., De Petrocellis, L., Maj, M., & Di Marzo, V. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300695 · Cited by 271
Self-citationOverweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH)
Sipe, J. C., Waalen, J., Gerber, A., & Beutler, E. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802954 · Cited by 259
Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell
Juan-Picó, P., Fuentes, E., Javier Bermúdez-Silva, F., Javier Díaz-Molina, F., Ripoll, C., Rodríguez de Fonseca, F., & Nadal, A. (2006) · Cell Calcium · doi:10.1016/j.ceca.2005.10.005 · Cited by 258
Côté, M., Mauriège, P., Bergeron, J., Alméras, N., Tremblay, A., Lemieux, I., & Després, J.-P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1711 · Cited by 230 · cited 2×
“In these patients, visceral fat contained significantly higher levels of 2-AG than sc fat, thus emphasizing the potential implication of the endocannabinoid system in the link between the metabolic syndrome and visceral, but not sc, adiposity (26).”
BackgroundVickers, S. P., Webster, L. J., Wyatt, A., Dourish, C. T., & Kennett, G. A. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1384-8 · Cited by 207
The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile
Poirier, B., Bidouard, J. ‐., Cadrouvele, C., Marniquet, X., Staels, B., O'Connor, S. E., Janiak, P., & Herbert, J. ‐. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00374.x · Cited by 203
The Endocannabinoid System in Human Keratinocytes
Maccarrone, M., Di Rienzo, M., Battista, N., Gasperi, V., Guerrieri, P., Rossi, A., & Finazzi-Agrò, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303994200 · Cited by 166
Gary‐Bobo, M., Elachouri, G., Scatton, B., Fur, G. L., Oury-Donat, F., & Bensaïd, M. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015040 · Cited by 160
Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain
Valenti, M., Vigan�, D., Casico, M. G., Rubino, T., Steardo, L., Parolaro, D., & Marzo, V. D. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3453-5 · Cited by 151
Cell lines derived from pancreatic islets
Hohmeier, H. E., & Newgard, C. B. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2004.04.017 · Cited by 122
Maccarrone, M., Bari, M., Rienzo, M. D., Finazzi‐Agrò, A., & Rossi, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302123200 · Cited by 113
Adipocytokines: Fat-Derived Humoral Mediators of Metabolic Homeostasis
Staiger, H., & Häring, H. (2005) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2004-830555 · Cited by 93
Chambers, A. P., Sharkey, K. A., & Koopmans, H. S. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.07.004 · Cited by 80
Cannabinoids and the Regulation of Ingestive Behaviour
Vickers, S. P., & Kennett, G. A. (2005) · Current Drug Targets · doi:10.2174/1389450053174514 · Cited by 74
Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells.
Levine, L. (2003) · Lipids in Health and Disease · doi:10.1186/1476-511x-2-1 · Cited by 72
Maccarrone, M., Fride, E., Bisogno, T., Bari, M., Cascio, M. G., Battista, N., Finazzi‐Agrò, A., Suris, R., Mechoulam, R., & Marzo, V. D. (2004) · Molecular Human Reproduction · doi:10.1093/molehr/gah130 · Cited by 68
[Detection, evaluation, and treatment of high blood cholesterol in adults].
(2001) · PubMed · Cited by 36
The induction of diabetes in rats by intramuscular administration of streptozotocin
Nakhoda, A., & Wong, H. A. (1979) · Cellular and Molecular Life Sciences · doi:10.1007/bf01953269 · Cited by 29
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“An up-regulation of CB1 receptors has been also reported in adipose tissue of genetically obese compared with lean mice (Bensaid et al., 2003), and elevated endocannabinoid levels have been detected in adipose tissue of obese compared with lean patients (Matias et al., 2006).”
BackgroundPertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Self-citationCani, P. D., Osto, M., Geurts, L., & Everard, A. (2012) · Gut Microbes · doi:10.4161/gmic.19625 · Cited by 864
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Self-citation
Metadata
- Authors
- Matias, I., Gonthier, M.-P., Orlando, P., Martiadis, V., De Petrocellis, L., Cervino, C., Petrosino, S., Hoareau, L., Festy, F., Pasquali, R., Roche, R., Maj, M., Pagotto, U., Monteleone, P., & Di Marzo, V.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-08-01
- Volume
- 91
- Issue
- 8
- Pages
- 3171-3180
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2117507851
- Cited by
- 656
- References
- 37
- FWCI
- 37.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.